Evolus (EOLS) Announces Proposed Public Offering of Common Stock

Evolus, Inc. (Nasdaq: EOLS) announced today that it has commenced a proposed underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. Evolus expects to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 15% of the shares of its common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the shares in the offering are to be sold by Evolus.

Evolus intends to use the net proceeds of the offering to continue to fund the U.S. growth of Jeuveau®, European pre-launch activities and general corporate purposes.

SVB Leerink, Stifel and Cantor are acting as joint bookrunning managers for the offering.

You May Also Be Interested In

• Venu Holding enters $250 million at-the-market stock offering agreement
• Bruker (BRKR) files mixed shelf
• Atossa Therapeutics closes $4.5 million registered direct offering